Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243408 | 1.00 | SYK (0.39) | SYKGPR119IRAK4TACR1BRAF | |
| SCHEMBL25533413 | 0.78 | USP30 (0.40) | SYKGPR119TACR1USP30 | |
| SCHEMBL25234548 | 0.78 | USP30 (0.40) | SYKGPR119TACR1USP30 | |
| SCHEMBL25419655 | 0.77 | IDH1 (0.41) | SYKTACR1HCRTR1USP30 | |
| SCHEMBL25438402 | 0.77 | IDH1 (0.41) | SYKTACR1HCRTR1USP30 | |
| SCHEMBL25533403 | 0.77 | IDH1 (0.41) | SYKTACR1HCRTR1USP30 | |
| SCHEMBL26126144 | 0.77 | IRAK4 (0.48) | GPR119IRAK4HCRTR2HCRTR1 | |
| SCHEMBL26126417 | 0.77 | MAPT (0.45) | SYKGPR119TACR1HCRTR1USP30 | |
| SCHEMBL25533466 | 0.76 | GPR119 (0.38) | GPR119IRAK4TACR1HCRTR1 | |
| SCHEMBL28544531 | 0.71 | USP30 (0.51) | SYKUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |